Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Shukui Qin; Masatoshi Kudo; Tim Meyer; Yuxian Bai; Yabing Guo; Zhiqiang Meng; Taroh Satoh; Donatella Marino; Éric Assenat; Songzi Li; Yaxi Chen; Frédéric Boisserie; Ramil Abdrashitov; Richard S. Finn; Arndt Vogel; Andrew X. Zhu

doi:10.1001/jamaoncol.2023.4003

Related publications

Article2019

RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Shukui Qin, Richard S. Finn, Masatoshi Kudo, Tim Meyer, Arndt Vogel, Michel Ducreux, Teresa Macarulla, Gianluca Tomasello, Frédéric Boisserie, Jeannie Hou, Xin Li, James Song, Andrew X. Zhu

Article2023

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Richard S. Finn, Shukui Qin, Masatoshi Kudo, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Gisoo Barnes, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel

Article2023

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Richard S. Finn, Shukui Qin, Masatoshi Kudo, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Gisoo Barnes, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel

Article2016

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

Andrew X. Zhu, Ari David Baron, Peter Malfertheiner, Masatoshi Kudo, Seiji Kawazoe, Denis Pezet, Florian Weißinger, Giovanni Brandi, Carlo Barone, Takuji Okusaka, Yoshiyuki Wada, Joon Oh Park, Baek‐Yeol Ryoo, Y. Choi, Hyun Cheol Chung, Chung‐Pin Li, Chia-Jui Yen, Kuan‐Der Lee, Shao-Chun Chang, Ling Yang, Paolo Abada, Ian Chau

Article2023

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).

Masatoshi Kudo, Richard S. Finn, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel, Shukui Qin

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Abstract

Discussion(0)

Related publications

RATIONALE 301 Study: Tislelizumab Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.

Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).